Results 151 to 160 of about 13,550 (188)

A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing <i>Klebsiella pneumoniae</i> infections and on ceftazidime/avibactam resistance development. [PDF]

Antimicrob Agents Chemother
Gatti M, Rinaldi M, Cojutti PG, Bonazzetti C, Siniscalchi A, Tonetti T, Ambretti S, Tedeschi S, Giannella M, Viale P, Pea F.   +10 more
europepmc   +1 more source

Overexpression of <i>bla</i>_SHV-12 caused by tandem amplification contributed to ceftazidime/avibactam resistance in hypervirulent and carbapenem-resistant <i>Klebsiella pneumoniae</i>. [PDF]

Emerg Microbes Infect
Liu C, Yi J, Yang P, Du C, Jiang F, Lu M, Du P, Shen N.   +7 more
europepmc   +1 more source

Mutant prevention concentrations, <i>in vitro</i> resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible <i>Klebsiella pneumoniae</i> isolates showing ceftazidime/avibactam resistance. [PDF]

Antimicrob Agents Chemother
Blanco-Martín T, González-Pinto L, Aja-Macaya P, Rodríguez-Pallares S, Sánchez-Peña L, Gato E, Fernández-López MdC, Outeda-García M, Rodríguez-Coello A, Pedraza-Merino R, Alonso-García I, Vázquez-Ucha JC, Martínez-Martínez L, Arca-Suárez J, Beceiro A, Bou G.   +15 more
europepmc   +1 more source

Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing <i>Pseudomonas aeruginosa</i>. [PDF]

Front Cell Infect Microbiol
Soto KD, Alcalde-Rico M, Ugalde JA, Olivares-Pacheco J, Quiroz V, Brito B, Rivas LM, Munita JM, García PC, Wozniak A.   +9 more
europepmc   +1 more source

Klebsiella pneumoniae carbapenemase variant 44 acquires ceftazidime-avibactam resistance by altering the conformation of active-site loops. [PDF]

J Biol Chem
Sun Z, Lin H, Hu L, Neetu N, Sankaran B, Wang J, Prasad BVV, Palzkill T.   +7 more
europepmc   +1 more source

Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy <i>bla</i>_KPC-2 to <i>bla</i>_KPC-189 during treatment of ST11 carbapenem-resistant <i>Klebsiella pneumoniae</i>. [PDF]

mSystems
Zhang X, Xie Y, Zhang Y, Lei T, Zhou L, Yao J, Liu L, Liu H, He J, Yu Y, Tu Y, Li X.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The primary pharmacology of ceftazidime/avibactam: resistancein vitro

Journal of Antimicrobial Chemotherapy, 2023
AbstractThis article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 2321–40 and 2341–52).
Wright W Nichols, Sushmita D Lahiri, Patricia A Bradford, Gregory G Stone   +3 more
openaire   +2 more sources